蛋白芯片用于筛选急性髓系白血病患者血清标志物的初步研究

目的利用生物素标记蛋白芯片筛选急性髓系白血病(AML)患者血清中可用于AML早期诊断、预后判断的血清标志物。方法采用生物素标记抗体芯片技术,对11名不同细胞遗传学和分子生物学特征的AML患者[分为预后良好组(5名),预后不良组(6名)]和5名健康体检者(对照组)的血清检测,采用芯片分析软件提取数据,获得的数据采用AAH-BLG-1数据分析软件作统计分析。结果 2个AML组与正常对照组相比,生长因子MFG-E8、osteoactivin、Hepassocin、M-CSF、M-CSF R、Insulin R,白细胞介素家族的IL-20、IL-3、IL-1 F8、IL-2 R alpha、IL-2 R beta、IL-1 R6凋亡因子(Fas)、粘附因子(ICAM-3)、趋化因子(CCL21)、载脂蛋白(Lipocalin-1)、跨膜蛋白(TMEFF1)、基质金属蛋白酶(MMP-3)和肿瘤坏死因子受体超家族的GFR alpha-4、TNF-alpha、TNFRF18、TNFRSF21等22个标志因子水平明显上调(P<0.05);预后不良组与预后良好组相比,IL-17RD、VEGF-D、IGFBP1、基质金属蛋白酶抑制剂TIMP-2、血管生成抑制剂Endostatin、蛋白水解酶uPA、趋化因子MIP-2、FGF-19、结合蛋白LBP、粘附分子L-selectin、载脂蛋白SAA等11个标志因子水平明显上调(P<0.05)。结论生物素蛋白质芯片共检测出33个AML血清标志物,证实这些标志物参与了AML细胞趋化、黏附、迁移、降解基质、恶性增殖、抗凋亡等过程。蛋白芯片有助于早期正确判断AML患者的预后,指导不同强度的个体化治疗。

A preliminary investigation:screening of serum protein markers by protein microarray technology in acute myeloid leukemia

Objective To screen serum biomarkers in patients with acute myeloid leukemia(AML) using biotin label-based antibody array,that can be applied to AML in its early diagnosis,conditions and prognosis.Methods Biotin label-based antibody array were used to detect 16 serum,including 11 AML of different cytogenetic and molecular biology,and 5 healthy controls.Using microarray analysis software to extract the data,the results obtained were analyzed by AAH-BLG-1 data analysis software.Results Compared with the control group,growth factor including MFG-E8,osteoactivin,Hepassocin,M-CSF,M-CSF R,Insulin R,and interleukin including IL-20,IL-3,IL-1 F8,IL-2 R alpha,IL-2 R beta,IL-1 R6,apoptosis including Fas,adhesis including ICAM-3,chemokine including CCL21,atherosclerosis including Lipocalin-1,Transmembrane protein TMEFF1,matrix metalloproteinase including MMP-3,TNFRSF including GFR alpha-4,TNF-alpha,TNFRF18,TNFRSF21 were all increased significantly(P<0.05).Poor prognosis group compared with the good prognosis group,interleukin including IL-17RD,growth factor including VEGF-D,IGFBP1,matrix metalloproteinase including TIMP-2,angiogensis including Endostatin,Proteolytic enzymes uPA,chemokine MIP-2,FGF-19,binding protein including LBP,adhesis including L-selectin,atherosclerosis SAA(P<0.05)were all increased significantly.Conclusion A total of 33 serum biomarkers in patients with AML were screened using biotin label-based antibody array.Confirmed their participation in the AML cell chemotaxis,adhesion,migration,degradation of the matrix,and malignant proliferation,anti-apoptotic process,can be helpful to a better judgment of the patients′prognosis as well as guiding individual.